← feed

Is NCT02245867 results overdue?

Yes — results are overdue. Primary completion was 2017-07-13; the FDAAA-801 reporting deadline (2018-07-13) passed 2900 days ago and no results are posted on ClinicalTrials.gov.

Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis

NCT IDNCT02245867 ↗
SponsorAlexion Pharmaceuticals, Inc. (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2017-07-13 (ACTUAL)
Reporting deadline2018-07-13 (completion + 365d)
Days overdue2900
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 6bd6be13c922f820… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02245867. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →